Objective The gene responsible for hereditary hemochromatosis close to the humanleukocyte antigen A locus was previously identified and designated as HFE. This study was performed to evaluate the clinical significance of two mutations, G282Yand H63Dof HFE, in Japanese patients with hepatic iron overload.
Introduction
The epidemiology of iron overload disorders shows marked geographical differences throughout the world. The major factors involved in iron balance are iron in the diet, iron absorption in the duodenum and iron loss by bleeding and cell sequestration from the skin and gut mucosa. Although the Japanese lifestyle, including diet, is now changing to that typical of Western populations, the numbers of patients with hemochromatosis have remained unchanged. Identification of the hereditary hemochromatosis gene designated as HFElocated close to the humanleukocyte antigen (HLA)A locus and the availability of testing for two point mutations, C282Yand H63D, that cause hereditary hemochromatosis have necessitated reevaluation of iron overload disorders (1) (2) (3) . Subsequent studies confirmed that most Caucasian patients with primary hemochromatosis are homozygous for C282Y (4) (5) (6) . More importantly, HFEmutations are not only responsible for primary hemochromatosis, but may also be involved in chronic hepatitis C (CHC) (7-1 1), non-alcoholic steatohepatitis (12) and porphyria cutanea tarda (3, 13, 14) . In contrast, no mutations of C282Yand only a few mutations of H63Dhave been reported in Oriental and Japanese populations (15, 16) . Although primary hemochromatosis is relatively rare in Japanese subjects, CHC,which is a major cause of hepatocellular carcinoma in Japan, is affected by iron hepatotoxicity and is highly responsive to iron reduction therapy (17) . The aims of this study were to clarify the epidemiological significance of C282Yand H63Din Japanese patients with primary hemochromatosis and CHCin which iron-induced oxidative stress might play an important role.
C282Yand H63D in Japanese Iron Overload following criteria; histologically proven heavy iron deposits in the liver and unknownetiology of iron overload. Heavy drinkers and patients with multiple transfusions or iron supplementation were excluded from the first patient group. Their clinical features including HLAclass 1 are summarized in Table 2 . There was no disease-specific HLAtype amongour hemochromatosis patients. Eight patients were unrelated to each other and had no family history of hemochromatosis, while the other 3 (2 menand a woman)were siblings from one family reported previously (18) . Seven patients had cirrhosis and the other four patients had pre-cirrhotic liver lesions. Diabetes requiring insulin therapy was noted in 6 patients, and general pigmentation was seen in 6 patients. One patient was positive for hepatitis B (HB) surface antigen and anti-HBe antibody, and another had antibody to hepatitis C virus (HCV). Their iron deposits, however, were very dense and compatible with hemochromatosis.
CHCwas diagnosed by biochemical liver damage for more than 6 months and positive test results for circulating HCV RNA.Complete responders to interferon were included in the second patient group. Heavy drinkers and patients with co-infection of HBvirus, multiple transfusions and/or iron supplementation were excluded from the CHCpatient group. Among the 94 patients with CHC, 56 patients were male and 38 female.
The third group included 2 male and 4 female patients with secondary hemochromatosis. Five patients with Wilson's disease whose livers had double metal loads of copper and iron were also included in this group. One patient with porphyria cutanea tarda was complicated by HCVinfection and hepatic iron load reported previously ( 19) . The fourth group of healthy volunteers included HBcarriers and subjects convalescing from HCVinfection who had low anti-HCV antibody titer and were negative for circulating HCVRNAwithout interferon treatment.
Wholeblood samples, 1 ml or more, were obtained from each subject with their informed consent. DNAsamples were extracted from peripheral leukocytes and the HFEgene region was amplified by polymerase chain reaction. Primers used to detect C282Y were F; 5'-TGGCAAGGGTAAACAGATCCand R; 5'-CTCAGGCACTCCTCTCAACC, and the restriction enzyme used was SnaBI (2). Primers used for H63D were F; 5'-ACATGGTTAAGGCCTGTTGC and R; 5'-GCCACATCTGGCTTGAAATT, and the enzyme used was Bell (3). Whenthe products indicated a mutation, direct sequencing was performed in each case. Control DNAsamples of C282Yand H63Dwere kindly provided by Dr. A. Piperno, Milan, Italy. Statistical analysis of mutation prevalence in patient groups was performed using Fisher's exact probability test. The figures in parentheses are subjects with secondary hemochromatosis in whomit was difficult to differentiate the disease state from primary hemochromatosis with regard to the degree of iron overload. *: Three patients, two menand one woman, were members of one family reported previously (1 8). Results Figure 1 shows the results of restriction enzymeassay for C282Y. All 3 10 subjects studied showed a combination of 845G/ 845G (normal/normal), and no mutation of C282Y. Figure 2 shows the results of restriction enzymeassay for H63Dand the distributions of H63Din the 4 groups are summarized in Table 3 . H63Dwas not found in any of the patients with primary hemochromatosis. One subject was homozygous and 4 were heterozygous for H63D among the patients with CHC. Twomale patients with alcoholic liver disease in the third group were found to be heterozygous for H63D. Among 15 1 healthy volunteers, 3 men and 5 womenwere heterozygous for H63D. As no mutations, either C282Yor H63D,were found in the HFEgene in patients with hemochromatosis, statistical analysis was not performed. The CHCgroup showed no significant differences in the prevalence of H63Das compared with the miscellaneous liver disease group or healthy volunteers (Table   4 ). There were no gender-related differences in the incidence of H63Din any of the patient groups or health volunteers (Table   5 ). The figures in parentheses are the chromosomal prevalence of H63D mutation. *: One patient with chronic hepatitis C was homozygous for the mutation, all other subjects listed here were heterozygous. All the subjects studied were free from C282Ymutation. 
Discussion
All the patients studied were native to the main islands of Japan. In the original report of HFE, 83% of patients with hereditary hemochromatosis were homozygous for C282Y( 1).
Reevaluation of the C282Yand H63Dmutation-free patients indicated that some patients had secondary hemochromatosis due to iron supplementation or alcoholism, but there was also a subgroup of mutation-free hemochromatosis patients (20) . In a previous study in Australia, 100% of hemochromatosis patients with familial history of hemochromatosis were homozygous for C282Y (2) . In Italy, 64% of patients had two copies of C282Y,suggesting that the disease is more heterogenous than reported in northern Europe (6). Thus, C282Ymu-tation-free hemochromatosiswas estimated to account for 0% to 20%of cases of hereditary hemochromatosis in Caucasians. In contrast to the reports from Europe, North Americaand Australia, all 1 1 of our patients with primary hemochromatosis were free from C282Ymutation. This observation, when extended to include patients with miscellaneous liver diseases and healthy subjects, remained unchanged and was consistent with previous population studies reported in Asian (15) and Japanese subjects (16) . No mutations of H63Dwere found in hemochromatosis patients probably because of the small number of subjects studied. The very low prevalence of HFEmutations, especially C282Y,in the Japanese population reflects the ethnic differences in primary hemochromatosis from Caucasian populations (16) . No specific locus of HLA-Awas noted in our patients with primary hemochromatosis as reported by Fujita et al (21) . Our hemochromatosis patients included three siblings reported previously ( 1 8) . Again, no commonlocus was found in their HLAclass 1. Based on these findings, it is likely that there are genetically different forms of primary hemochromatosis including juvenile hemochromatosis and hemochromatosis of African populations (20, (22) (23) (24) (25) (26) (27) . A candidate gene for juvenile hemochromatosis has been reported to exist in lq (28) . There is currently no evidence indicating any genetic background or environmental factors involved in hemochromatosis in Japan, so further studies are needed to characterize Japanese hemochromatosis patients. HFEprotein has a high affinity to transferrin receptors (29) . Complex of HFEprotein and transferrin receptors expressed at the basal membrane of immature cryptocytes might be a key sensor of body iron storage. Dietary iron is absorbed through DMT1at microvilli of mature apical enterocytes, and exported to the blood stream via ferroportinl in the basolateral membrane. Searches for genes responsible for hemochromatosis should include such functional proteins regulating iron absorption (30) . Iron load plays an important role in the pathogenesis of CHC (17) . Therefore, the CHCpatients studied here were a selected population with regard to iron metabolism. Despite such selection, there were no C282Ymutations and only 6 chromosomes with H63Dmutation among 1 88 chromosomes studied (3.2%). The prevalence of H63Dmutation in our patients with CHCwas not different from the value of 2/108 (1.9%) for miscellaneous liver diseases or that of 8/302 (2.6%) in healthy volunteers. There is general agreement that the occurrence of C282Ymutation can not fully explain liver iron load in CHC but favors its progression (7-ll) . With the exception of one study on porphyria cutanea tarda from Italy, there have been no previous studies concerning H63Din iron overload disorders (14) . No C282Y mutations and an incidence of 1.3% for H63Dmutation were found in 200 healthy individuals. A population study on Asian subjects showed incidences of 0 to 0.01% for C282Y mutation and 0.9 to 1.2% for H63D mutation (15) . Similar results were reported in a preliminary study in a Japanese population (16) . Our data taken together with the results described above suggested that H63Dmutation also seems not to be involved in iron load in Japanese patients with CHC.Although most Japanese subjects were free from either C282Y or H63Dmutation, this does not mean that Japanese patients with CHCare free from iron-induced oxidative stress because storage of small amounts of iron is sufficient for free radical generation.
In conclusion, we postulated that the epidemiological significance of C282Y and H63D mutations in the HFE gene is negligible in Japanese patients with chronic liver diseases even wheniron load plays an important role.
